Aardvark Therapeutics has followed up filings and speculation with a $94 million initial public offering, putting itself on ...

Aardvark’s lead candidate ARD-101 is being investigated in a Phase III study for hyperphagia in Prader-Willi syndrome.

Metsera expects its cash will last into 2027. Two other life science companies went public this past week. Here’s a look at those IPOs: Maze Therapeutics Finds Way to $140M IPO for Chronic ...

This summary highlights significant health news, covering topics such as HIV treatment during U.S. aid pauses, Pfizer's diversity program legal settlement, AstraZeneca's halted UK investment, data ...

Sionna Therapeutics is eyeing a $156 million IPO as the cystic-fibrosis-focused biotech looks to take its lead candidate into ...

The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...

Aadvark, which will list on the Nasdaq under the ticker “AARD” Feb. 13, will have the opportunity to bring in roughly $14.1 ...

Sionna Therapeutics has closed its initial public offering, raising $191 million for its pipeline of therapies for cystic ...

Metsera and Maze Therapeutics are the second and third biotechnology firms this year to go public, raising $275 million and $140 million, respectively, in a pair of new stock offerings priced ...

GT Medical Technologies, announced that it has raised $37 million in Series D financing round. The financing round was led ...